These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 2360913)
1. On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat. Balasubramaniam S; Simons LA; Chang S; Roach PD; Nestel PJ Atherosclerosis; 1990 May; 82(1-2):1-5. PubMed ID: 2360913 [TBL] [Abstract][Full Text] [Related]
2. TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters. Sugiyama Y; Ishikawa E; Odaka H; Miki N; Tawada H; Ikeda H Atherosclerosis; 1995 Feb; 113(1):71-8. PubMed ID: 7755657 [TBL] [Abstract][Full Text] [Related]
3. A selective inhibitor of intestinal ACAT, EAB309 suppresses both intestinal and hepatic cholesterol output and stimulates chylomicron removal. Umeda Y; Hirano T; Kako Y; Kamagata K; Okuyama K; Suzuki K Life Sci; 1998; 63(13):PL187-95. PubMed ID: 9763214 [TBL] [Abstract][Full Text] [Related]
4. Regulation of acylcoenzyme A. Cholesterol acyltransferase and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by lipoproteins in the intestine of parabiont rats. Purdy BH; Field FJ J Clin Invest; 1984 Aug; 74(2):351-7. PubMed ID: 6746898 [TBL] [Abstract][Full Text] [Related]
5. Regulation of ovarian cholesterol metabolism: control of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase. Schuler LA; Toaff ME; Strauss JF Endocrinology; 1981 Apr; 108(4):1476-86. PubMed ID: 7472277 [TBL] [Abstract][Full Text] [Related]
6. The effect of hypothyroidism and thyroxine replacement on hepatic and intestinal HMG-CoA reductase and ACAT activities and biliary lipids in the rat. Field FJ; Albright E; Mathur SN Metabolism; 1986 Dec; 35(12):1085-9. PubMed ID: 3784912 [TBL] [Abstract][Full Text] [Related]
7. Role of the intestinal acyl-CoA:cholesterol acyltransferase activity in the hyperresponse of diabetic rats to dietary cholesterol. Maechler P; Wollheim CB; Bentzen CL; Niesor E J Lipid Res; 1992 Oct; 33(10):1475-84. PubMed ID: 1431572 [TBL] [Abstract][Full Text] [Related]
12. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats. Uchida T; Aoyama K; Watanabe T; Higuchi S Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741 [TBL] [Abstract][Full Text] [Related]
13. Effects of dietary soybean lecithin on plasma lipid transport and hepatic cholesterol metabolism in rats. LeBlanc MJ; Brunet S; Bouchard G; Lamireau T; Yousef IM; Gavino V; Lévy E; Tuchweber B J Nutr Biochem; 2003 Jan; 14(1):40-8. PubMed ID: 12559476 [TBL] [Abstract][Full Text] [Related]
14. Demonstration of a direct effect on hepatic acyl CoA: cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster. Burrier RE; Deren S; McGregor DG; Hoos LM; Smith AA; Davis HR Biochem Pharmacol; 1994 Apr; 47(9):1545-51. PubMed ID: 8185666 [TBL] [Abstract][Full Text] [Related]
15. CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. Largis EE; Wang CH; DeVries VG; Schaffer SA J Lipid Res; 1989 May; 30(5):681-90. PubMed ID: 2760542 [TBL] [Abstract][Full Text] [Related]